cost containment “Cost containment measures are not just a Polish story, but a European reality,” says Marcin Hanczaruk, general manager at Amgen. “The Reimbursement Act is a real revolution, but it has brought both benefits and shortcomings. One consequence is that Poland has the lowest average price of medicine in the European…
Poland Thanks to its strategic location, EU membership, and low cost base, Poland has successfully attracted investments from the global pharmaceutical industry. Today, over half of the top 30 pharma companies operating in Poland have manufacturing facilities or functional hubs (IT center, Clinical research, Shared Services, etc) in the country.
Poland Despite an overall growth slowdown in the Polish market, the OTC segment still offers many opportunities to pharma companies. Here are the top 10 OTC companies based on growth figure in 2013.
AstraZeneca Poland You have been quite recently appointed at the head of the Polish affiliate of AstraZeneca. With which personal ambitions did you come and what was the mission you were given when you took office? I would not say that I have been given a mission, but that I have been…
Astellas Poland You were appointed general manager of Astellas Poland in early 2006, only a bit after Astellas Pharma Inc. was established, on April 1, 2005 through the merger of the mother companies Yamanouchi and Fujisawa. Could you describe to our readers the evolution of the affiliate since the merger? Astellas has…
Bausch & Lomb Poland BAUSCH + LOMB has over 150 years of heritage and has always been associated with optics and ophthalmology. Therefore the company has been able to build a very strong brand image throughout the years and is today recognized as the best in eye health. Would you say it is an…
Cegedim Poland Given Cegedim’s global reach and your 13 year experience of operating as a consultant to the Polish pharma industry, how would you describe the market to the international readers of Pharmaceutical Executive? On the one hand the pressures and incentives influencing the main stakeholders are the same as elsewhere. But…
Bristol-Myers Squibb Poland As Squibb Corporation and Bristol-Myers merged in 1989, Bristol-Myers Squibb has been officially operating in this market since that date, but the affiliate has a long history previous to that. What is the importance of Poland today for the group’s global strategy? About six years ago, there was a need…
Nycomed Poland As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous year, but still managed to grow by 3,3% according to IMS data, which is in line with the market. This…
Ipsen Poland When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How has Poland alone performed in the same period? It is my personal privilege and pride to say that 2010 was an extremely good…
Servier Poland Unlike many pharmaceutical companies, Servier fully operates in all pharma business activities in Poland: research, drug manufacturing and distribution, and health education. Considering your extensive international and regional experience in Romania, Russia, and Bulgaria, but also Vietnam, what is unique here? What is there in Poland that is attracting the…
Genzyme Poland With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market, in bio-surgery, in oncology, and also in transplant. What area has been driving the growth in 2010? In value terms,…
See our Cookie Privacy Policy Here
